CG
CRMD icon

Cutler Group’s CorMedix CRMD Stock Holding History

Cutler Group’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-820
Closed -$1K – 6606
2016
Q3 		$1K Buy
+820
New +$7.67K ﹤0.01% 6056

Other funds holding CRMD

EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SC
Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Cutler Group's CRMD Position: Q4 2017 in Review

Cutler Group sold out of CorMedix (CRMD) in Q4 2017, closing a stake of 240 shares.

Cutler Group first reported a position in CRMD in Q4 2015 and held it in 8 quarters. The position peaked at $18K in Q1 2016. 34 funds tracked by Wall St. Rank hold CRMD as of Q4 2017.

  • Cutler Group reported no remaining CorMedix position as of Q4 2017 after selling out during the quarter.
  • Cutler Group sold 240 CorMedix shares in Q4 2017.
  • Cutler Group first reported a position in CorMedix in Q4 2015 and held it in 8 quarters.
  • Cutler Group's CorMedix position peaked at $18K in Q1 2016.
  • 34 funds tracked by Wall St. Rank held CorMedix as of Q4 2017.

Based on Cutler Group's 13F filing for Q4 2017, filed 17 Jan 2018.